Sinclair Pharma PLC (LSE:SPH) - Share price - Overview

Stock Report

Sinclair Pharma PLC SPH

Last Price
GBX26.75

Day Change
0.25|0.94%

As of 22/09/2017
16:32:16 BST | GBX
Minimum 15 Minutes Delay.

Last Close26.50p
Day Range26.16 - 27.00
Mkt Cap134.80Mil
52-Wk Range26.00 - 36.35
Yield %0.00
ISINGB0033856740
Volume171,616
P/E-7.15
P/S4.41
P/CF-10.43

Share Price

Total Returns 22/09/2017

 Chg (%)  
More ...
Sinclair Pharma PLC-9.32 
FTSE 100 TR GBP-0.82
 
Financials
201420152016
More ...
Income Statement
Turnover63.5627.8430.19
Operating Profit-1.79-11.73-12.10
Net Profit-4.09-23.37-22.16
Reported EPS-0.90-4.70-4.45
Balance Sheet
Current Assets54.6747.9533.94
Non Current Assets246.95237.47150.66
Total Assets302.72285.42184.60
Current Liabilities42.8846.7526.88
Total Liabilities184.80179.8584.28
Total Equity117.92105.57100.32
Cash Flow
Operating Cash Flow-4.369.98-10.84
Net Change in Cash12.68-5.092.18
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-6.42-1.21--22.18---
20181.760.60-44.58---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
04/10/2016PurchaseMr. Jeff Thompson29.13150,00043,688.00
30/09/2016Transfer inMr. Chris Spooner0.001,101,3150.00

Company Profile

Sinclair Pharma PLC is a specialty pharmaceutical company focused on Dermatology, in particular - Aesthetics, Wound care, and Skin care.

Sector

Drug Manufacturers - Specialty & Generic

Market Position

820 of 1836 Companies

Index

FTSE AIM All Share

Outlook

(19/09/2017) ce - "We remain confident we will deliver strong sales growth in the second half and an adjusted EBITDA profit for the year ending 31 December 2017"

Next Event 31/12/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)266.8113.166.87
Div Yld (E)0.003.994.18
PEG (E)0.000.760.90
ROCE-146.77194.20214.15
Op Mrgn-57.32-3.46-38.07
EPS Grwth0.0021.6319.05
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy2
Hold1
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Grahame Cook
Chief Executive OfficerMr. Chris Spooner
Chief Financial OfficerAlan Olby
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.